Home  >  News
News
+ Font Resize -

Endonovo updates on acquisition of PEMF assets, clinical pipeline & pre-clinical study

Los Angeles, California
Saturday, December 30, 2017, 14:00 Hrs  [IST]

Endonovo Therapeutics, a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, provided an update on the acquisition of the PEMF assets from Rio Grande Neurosciences, its clinical pipeline targeting central nervous system disorders and its pre-clinical study on post-MI remodeling.

The company is currently in the process of transferring all of the assets it has acquired from Rio Grande Neurosciences and registering with the Food and Drug Administration to become regulatory compliant. These important steps must be completed in order for the company to pursue the commercialization its tPEMF technology.

Endonovo's pipeline in central nervous system (CN”) disorders includes currently planned clinical trials to evaluate its tPEMF therapy in post-concussion syndrome, acute sports-related concussion and an open label study to generate preliminary clinical data on adjunctive tPEMF therapy in patients with relapsing-remitting multiple sclerosis. The company is seeking to further expand its clinical pipeline to evaluate its tPEMF therapy in ischemic stroke and other neurodegenerative diseases.

The company believes that its non-invasive technology has the potential to become standard care in the treatment of CNS disorders because its technology operates via induction (the generation of small electric currents in brain tissue) to quell neuroinflammation; promote neuroprotection and the formation of new blood vessels. The company believes that its technology addresses the major setback limiting the development of treatments for CNS disorders, the blood-brain-barrier (BBB), which prevents the delivery of efficacious levels of drugs to the central nervous system (CNS). Unlike pharmaceutical-based treatments, the blood-brain-barrier cannot hinder the delivery of the company's tPEMF therapy to the brain parenchyma, which is one of the major hurdles to the effective treatment of CNS disorders.

Furthermore, the company is finalizing the data on its pre-clinical study to assess the efficacy of its non-invasive electroceutical for the treatment and prevention of heart failure following myocardial infarction and will release the results early in the first quarter of 2018. Endonovo had previously released data from its pre-clinical study, which found treatment with the company's non-invasive electroceutical two or three times per day resulted in significantly increased cardiac function and reduced ventricular remodeling. Treatment with the company's Immunotronics technology two or three times per day resulted in significantly improved Ejection Fraction (EF), Fractional Shortening (FS), Heart Weight-to-Body Weight Ratio (HW/BW), Left Ventricular Diastolic Pressure (LVDP), Left Ventricular End-Systolic Diameter (LVESD), and Interventricular Septal Dimension at Systole (IVSS).

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
ipc_2018
cphi-india_Banner-150x60
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |